Merger of Iomai, Intercell clears waiting period hurdle

By Lisa Kerner

Charlotte, N.C., June 3 - The Federal Trade Commission granted early termination of the Hart-Scott-Rodino waiting period in the proposed merger of Iomai Corp. and Intercell AG, it was reported in a form 8-K filing with the Securities and Exchange Commission.

The transaction, expected to close in the third quarter, requires the approval of Iomai stockholders and clearance by the Committee on Foreign Investment in the United States, the filing stated.

On May 12, Intercell announced it would acquire Iomai for $6.60 a share, or a total of $189 million.

Intercell is a biotechnology company based in Vienna.

Iomai is a Gaithersburg, Md., developer of vaccines and immune system stimulants.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.